ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Melbourne (Australia) | April 22, 2026
Telix today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.
ProstACT Global is an international, multi-center, Phase 3 trial evaluating Telix’s lead prostate-specific membrane antigen (PSMA) targeted lutetium radio antibody-drug conjugate (rADC) therapy, TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan), in combination with standard of care (SoC) versus SoC alone. The study is designed to reflect real-world global clinical practice with the aim to support broad geographic adoption in the evolving prostate cancer treatment landscape.
Part 1 of the trial is a safety and dosimetry lead-in, assessing the tolerability, biodistribution, and radiation dose profile of TLX591-Tx when administered in combination with SoC in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
The selection of this abstract as a late-breaking oral presentation at ASCO underscores the potential clinical significance of the ProstACT Global study and Telix’s continued leadership in advancing next-generation radiopharmaceutical therapies for prostate cancer.
Presentation details are as follows:
Presenting Author: Pedro C. Barata, MD, MSc, University Hospitals Seidman Cancer Center, Cleveland, OH.
Abstract Number: LBA5009.
ClinicalTrials.gov ID: NCT06520345
Date, Time and Location: June 1, 2026, 3:12 p.m. – 3:24 p.m. CDT, Arie Crown Theater
Session Type and Title: Clinical Science Symposium – Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer
Late-breaking abstracts will be made publicly available at 7:00 a.m. CDT (8:00 a.m. EDT) on the day of presentation. Additional information can be found at www.asco.org
TLX591-Tx has not received a marketing authorization in any jurisdiction